JP2016512230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512230A5 JP2016512230A5 JP2015562555A JP2015562555A JP2016512230A5 JP 2016512230 A5 JP2016512230 A5 JP 2016512230A5 JP 2015562555 A JP2015562555 A JP 2015562555A JP 2015562555 A JP2015562555 A JP 2015562555A JP 2016512230 A5 JP2016512230 A5 JP 2016512230A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- parenteral composition
- use according
- levodopa
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004475 Arginine Substances 0.000 claims 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 229960004502 levodopa Drugs 0.000 claims 6
- 229960004205 carbidopa Drugs 0.000 claims 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 5
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 claims 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 | |
| US61/779,357 | 2013-03-13 | ||
| PCT/IL2014/050261 WO2014141261A1 (en) | 2013-03-13 | 2014-03-13 | Method for treatment of parkinson's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019008215A Division JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512230A JP2016512230A (ja) | 2016-04-25 |
| JP2016512230A5 true JP2016512230A5 (enExample) | 2017-04-13 |
| JP6472391B2 JP6472391B2 (ja) | 2019-02-20 |
Family
ID=50513395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562555A Active JP6472391B2 (ja) | 2013-03-13 | 2014-03-13 | パーキンソン病の治療方法 |
| JP2019008215A Active JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019008215A Active JP6625773B2 (ja) | 2013-03-13 | 2019-01-22 | パーキンソン病の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160022573A1 (enExample) |
| EP (2) | EP3892266A1 (enExample) |
| JP (2) | JP6472391B2 (enExample) |
| KR (1) | KR102209353B1 (enExample) |
| CN (2) | CN105209029A (enExample) |
| AU (1) | AU2014229127B2 (enExample) |
| BR (1) | BR112015022390A8 (enExample) |
| CA (1) | CA2904838C (enExample) |
| CL (1) | CL2015002641A1 (enExample) |
| DK (1) | DK2968218T3 (enExample) |
| ES (1) | ES2889626T3 (enExample) |
| HR (1) | HRP20211442T1 (enExample) |
| HU (1) | HUE056006T2 (enExample) |
| IL (1) | IL266648B (enExample) |
| MX (1) | MX365206B (enExample) |
| PL (1) | PL2968218T3 (enExample) |
| PT (1) | PT2968218T (enExample) |
| RU (2) | RU2018144700A (enExample) |
| SG (2) | SG11201507538UA (enExample) |
| WO (1) | WO2014141261A1 (enExample) |
| ZA (1) | ZA201507621B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627655T3 (es) | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| JP5902705B2 (ja) | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| PL2640370T3 (pl) | 2010-11-15 | 2018-09-28 | Neuroderm Ltd | Kompozycje do dostarczania przezskórnego substancji czynnych |
| PT3116475T (pt) * | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| ES2973289T3 (es) | 2014-09-04 | 2024-06-19 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona |
| JP6567049B2 (ja) | 2014-10-21 | 2019-08-28 | アッヴィ・インコーポレイテッド | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| SMT202100247T1 (it) * | 2017-06-05 | 2021-05-07 | Dizlin Pharmaceuticals Ab | Soluzione per infusione di levodopa |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| WO2019147934A1 (en) * | 2018-01-29 | 2019-08-01 | Sackner Bernstein Jonathan | Methods for dopamine modulation in human neurologic diseases |
| JP2021517128A (ja) * | 2018-03-29 | 2021-07-15 | アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー | レボドパ分割用量組成物および使用 |
| CA3117983A1 (en) | 2018-11-15 | 2020-05-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| WO2022047298A1 (en) * | 2020-08-31 | 2022-03-03 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| KR101617990B1 (ko) * | 2005-06-08 | 2016-05-03 | 오리온 코포레이션 | 경구 용량 형태 |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| ES2627655T3 (es) * | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| JP5902705B2 (ja) * | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
-
2014
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en not_active Ceased
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active Active
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en not_active Abandoned
-
2024
- 2024-07-05 US US18/764,647 patent/US20250177292A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512230A5 (enExample) | ||
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2012527447A5 (enExample) | ||
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| MX355742B (es) | Análogos deuterados del ácido 4-hidroxibutírico. | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| PH12019550113A1 (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| MX359989B (es) | Fármacos antivirales para el tratamiento de la infección por arenavirus. | |
| CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
| MX2017009837A (es) | Dinucleotidos ciclicos utiles para el tratamiento de cancer entre otros. | |
| JO3583B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| UA118680C2 (uk) | Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в | |
| CO2017010162A2 (es) | Nucleótidos de purina ß-d-2'-desoxi-2'-α-fluoro-2'-ß-c-sustituidos-2-modificados-n6-sustituidos para el tratamiento del virus de la hepatitis c | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| EA201391737A1 (ru) | Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения |